A rare, benign neoplasm that arises from the peritoneum and is characterized by the presence of gland like structures. Cytologic atypia is absent.
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation on benign peritoneal mesothelioma is limited due to its extreme rarity, which affects fewer than 1,000 people worldwide. This rarity results in a lack of systematic clinical studies and comprehensive data collection, making it challenging to establish a clear understanding of the disease's characteristics and management.
To navigate your care for benign peritoneal mesothelioma, consider consulting with an oncologist who specializes in rare tumors or mesothelioma. They can provide insights into the latest treatment options and clinical trials. You may also find valuable information and support through resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. While no patient organizations are currently identified for this condition, staying connected with broader cancer support networks may be beneficial.
There are several orphan drugs designated for benign peritoneal mesothelioma, including nivolumab and ipilimumab, which are FDA-approved. Additionally, multiple drugs are in development, such as various targeted therapies and immunotherapies. However, no clinical trial data is currently available. For ongoing research, you can search for studies at ClinicalTrials.gov.
Actionable guidance for navigating care for benign peritoneal mesothelioma
To navigate your care for benign peritoneal mesothelioma, consider consulting with an oncologist who specializes in rare tumors or mesothelioma. They can provide insights into the latest treatment options and clinical trials. You may also find valuable information and support through resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. While no patient organizations are currently identified for this condition, staying connected with broader cancer support networks may be beneficial.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation on benign peritoneal mesothelioma is limited due to its extreme rarity, which affects fewer than 1,000 people worldwide. This rarity results in a lack of systematic clinical studies and comprehensive data collection, making it challenging to establish a clear understanding of the disease's characteristics and management.
To navigate your care for benign peritoneal mesothelioma, consider consulting with an oncologist who specializes in rare tumors or mesothelioma. They can provide insights into the latest treatment options and clinical trials. You may also find valuable information and support through resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. While no patient organizations are currently identified for this condition, staying connected with broader cancer support networks may be beneficial.
There are several orphan drugs designated for benign peritoneal mesothelioma, including nivolumab and ipilimumab, which are FDA-approved. Additionally, multiple drugs are in development, such as various targeted therapies and immunotherapies. However, no clinical trial data is currently available. For ongoing research, you can search for studies at ClinicalTrials.gov.
Actionable guidance for navigating care for benign peritoneal mesothelioma
To navigate your care for benign peritoneal mesothelioma, consider consulting with an oncologist who specializes in rare tumors or mesothelioma. They can provide insights into the latest treatment options and clinical trials. You may also find valuable information and support through resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. While no patient organizations are currently identified for this condition, staying connected with broader cancer support networks may be beneficial.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation on benign peritoneal mesothelioma is limited due to its extreme rarity, which affects fewer than 1,000 people worldwide. This rarity results in a lack of systematic clinical studies and comprehensive data collection, making it challenging to establish a clear understanding of the disease's characteristics and management.
To navigate your care for benign peritoneal mesothelioma, consider consulting with an oncologist who specializes in rare tumors or mesothelioma. They can provide insights into the latest treatment options and clinical trials. You may also find valuable information and support through resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. While no patient organizations are currently identified for this condition, staying connected with broader cancer support networks may be beneficial.
There are several orphan drugs designated for benign peritoneal mesothelioma, including nivolumab and ipilimumab, which are FDA-approved. Additionally, multiple drugs are in development, such as various targeted therapies and immunotherapies. However, no clinical trial data is currently available. For ongoing research, you can search for studies at ClinicalTrials.gov.
Actionable guidance for navigating care for benign peritoneal mesothelioma
To navigate your care for benign peritoneal mesothelioma, consider consulting with an oncologist who specializes in rare tumors or mesothelioma. They can provide insights into the latest treatment options and clinical trials. You may also find valuable information and support through resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. While no patient organizations are currently identified for this condition, staying connected with broader cancer support networks may be beneficial.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 5, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.